Item 8.01. Other Events.

On December 15, 2020, ARCA biopharma, Inc., or the Company, announced that the first patients have been enrolled in ASPEN­COVID­19, the Phase 2b clinical trial evaluating rNAPc2 (AB201) as a potential treatment for patients hospitalized with COVID-19. The first patient was enrolled at the University of Colorado Hospital on December 10, 2020, with a total of 5 patients randomized to date. The Company currently anticipates topline trial data from this Phase 2b clinical trial in the second quarter of 2021. The press release related to these items is filed as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.


Exhibit Number          Description
99.1                      Press Release titled "ARCA biopharma Announces First
                        Patients Enrolled in ASPEN­COVID­19 Phase 2b Clinical Trial
                        Evaluating rNAPc2 (AB201) as a Potential Treatment for
                        COVID-19" dated December 15, 2020  .

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses